ADVERTISEMENT
data from an staggering 99 million individuals across eight nations: Argentina, Australia, Canada, France, Denmark, Finland, New Zealand, and Scotland. By focusing on a massive cohort primarily aged between 20 and 59, the study provided a clear, statistically significant look at how different populations responded to the Pfizer, Moderna, and AstraZeneca continue reading …
ADVERTISEMENT